EA
ITCI

Emerald Acquisition’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Emerald Acquisition’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$225K Sell
14,756
-18,367
-55% -$743K ﹤0.01% 2662
2016
Q2 		$1.28M Buy
+33,123
New +$1.19M ﹤0.01% 2032

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Emerald Acquisition's ITCI Position: Q3 2016 in Review

Emerald Acquisition reduced its Intra-Cellular Therapies Inc. (ITCI) stake by 55% in Q3 2016, selling an estimated $743K and leaving 14,756 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #2662.

Emerald Acquisition first reported a position in ITCI in Q2 2016 and has held it in 2 quarters since. The position peaked at $1.28M in Q2 2016. 131 funds tracked by Wall St. Rank hold ITCI as of Q3 2016.

  • Emerald Acquisition held 14,756 shares of Intra-Cellular Therapies Inc. worth $225K as of Q3 2016.
  • Emerald Acquisition sold 18,367 Intra-Cellular Therapies Inc. shares in Q3 2016, an estimated $743K.
  • Intra-Cellular Therapies Inc. made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2662 holding.
  • Emerald Acquisition first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Intra-Cellular Therapies Inc. position peaked at $1.28M in Q2 2016.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.